These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33045968)

  • 1.
    Yadavar-Nikravesh MS; Milani A; Vahabpour R; Khoobi M; Bakhshandeh H; Bolhassani A
    Curr HIV Res; 2021; 19(2):138-146. PubMed ID: 33045968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure.
    Jin H; Li D; Lin MH; Li L; Harrich D
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32276443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes.
    Tang X; Lu H; Dooner M; Chapman S; Quesenberry PJ; Ramratnam B
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficiency of Tat Cell Penetrating Peptide for Intracellular Uptake of HIV-1 Nef Expressed in E. coli and Mammalian Cell.
    Kadkhodayan S; Bolhassani A; Sadat SM; Irani S; Fotouhi F
    Curr Drug Deliv; 2017; 14(4):536-542. PubMed ID: 27719633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIV-1 Tat Protein: Mechanism of Action and Target for HIV-1 Cure Strategies.
    Rice AP
    Curr Pharm Des; 2017; 23(28):4098-4102. PubMed ID: 28677507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking HIV replication by targeting Tat protein.
    Hamy F; Gelus N; Zeller M; Lazdins JL; Bailly C; Klimkait T
    Chem Biol; 2000 Sep; 7(9):669-76. PubMed ID: 10980447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent status of HIV-1 gene expression inhibitors.
    Baba M
    Antiviral Res; 2006 Sep; 71(2-3):301-6. PubMed ID: 16488488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription.
    Mousseau G; Clementz MA; Bakeman WN; Nagarsheth N; Cameron M; Shi J; Baran P; Fromentin R; Chomont N; Valente ST
    Cell Host Microbe; 2012 Jul; 12(1):97-108. PubMed ID: 22817991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a dual reporter screening assay for distinguishing the inhibition of HIV Tat-mediated transcription from off-target effects.
    Shin Y; Choi BS; Kim KC; Kang C; Kim K; Yoon CH
    J Virol Methods; 2017 Nov; 249():1-9. PubMed ID: 28807730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Contributing to the Antiviral Effectiveness of Tenofovir.
    Murphy RA; Valentovic MA
    J Pharmacol Exp Ther; 2017 Nov; 363(2):156-163. PubMed ID: 28860352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of HIV-1 gene expression and transcription.
    Baba M
    Curr Top Med Chem; 2004; 4(9):871-82. PubMed ID: 15134546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction, expression, and purification of HIV-TAT-survivin (T34A) mutant: a pro-apoptosis protein in Escherichia coli.
    Ma X; Zheng W; Wei D; Ma Y; Wang T; Wang J; Liu Q; Yang S
    Protein Expr Purif; 2006 May; 47(1):36-44. PubMed ID: 16260148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
    Imaz A; Podzamczer D
    Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Host Factors on the Regulation of Tat-Mediated HIV-1 Transcription.
    Mousseau G; Valente ST
    Curr Pharm Des; 2017; 23(28):4079-4090. PubMed ID: 28641539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.
    Lee KH; Lee JU; Ku NS; Jeong SJ; Han SH; Choi JY; Song YG; Kim JM
    Yonsei Med J; 2017 Jul; 58(4):770-777. PubMed ID: 28540990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reconstruction of an intracellular transduction system based on HIV-1 TAT protein transduction domain].
    Guo AH; Liu ZF; Sun XG; Li HY; Deng P; Jiang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 May; 26(5):545-8. PubMed ID: 16762844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HBV effect of TAT- HBV targeted ribonuclease.
    Ding J; Liu J; Xue CF; Gong WD; Li YH; Zhao Y
    World J Gastroenterol; 2003 Jul; 9(7):1525-8. PubMed ID: 12854156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semen Exosomes Promote Transcriptional Silencing of HIV-1 by Disrupting NF-κB/Sp1/Tat Circuitry.
    Welch JL; Kaddour H; Schlievert PM; Stapleton JT; Okeoma CM
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30111566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
    Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
    mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.
    Casadellà M; Noguera-Julian M; Sunpath H; Gordon M; Rodriguez C; Parera M; Kuritzkes DR; Marconi VC; Paredes R
    AIDS; 2016 Apr; 30(7):1137-40. PubMed ID: 26807968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.